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Abstract Purpose: In most extra-
corporeal membrane oxygenation
(ECMO) centers patients are heavily
sedated to prevent accidental
decannulation and bleeding compli-
cations. In ventilated adults not on
ECMO, daily sedation interruption
protocols improve short- and long-
term outcome. This study aims to
evaluate safety and feasibility of
sedation interruption following
cannulation in neonates on ECMO.
Methods: Prospective observational
study in 20 neonates (0.17–5.8 days
of age) admitted for ECMO treat-
ment. Midazolam (n = 20) and
morphine (n = 18) infusions were
discontinued within 30 min after
cannulation. Pain and sedation were
regularly assessed using COMFORT-
B and visual analog scale (VAS)
scores. Midazolam and/or morphine
were restarted and titrated according
to protocolized treatment algorithms.
Results: Median (interquartile
range, IQR) time without any seda-
tives was 10.3 h (5.0–24.1 h). Median
interruption duration for midazolam
was 16.5 h (6.6–29.6 h), and for
morphine was 11.2 h (6.7–39.4 h).
During this period no accidental
extubations, decannulations or
bleeding complications occurred.
Conclusions: This is the ﬁrst study
to show that interruption of sedatives
and analgesics following cannulation
in neonates on ECMO is safe and
feasible. Interruption times are
2–3 times longer than reported for
adult ICU patients not on ECMO.
Further trials are needed to substan-
tiate these ﬁndings and evaluate
short- and long-term outcomes.
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Extracorporeal membrane oxygenation (ECMO) is a form
of cardiopulmonary bypass for patients with pulmonary or
circulatory failure unresponsive to conventional treatment.
Most patients are heavily sedated to prevent accidental
decannulation or impeded ECMO ﬂow due to movement
or suboptimal cannula position. However, prolonged and
high cumulative doses of opioids and benzodiazepines
have been associated with tolerance, physical dependency,
and consequently withdrawal syndrome in neonates and
children [1–5]. Sedation guidelines for pediatric ICU
patients have been developed but are in part hampered by
the lack of high-quality evidence, and exclude neonates
and ECMO patients [6, 7]. Strategies to decrease cumu-
lative doses and duration of continuous infusions with the
intent to reduce consequent adverse events include daily
interruption or even complete withholding of continuous
sedation [8, 9]. The latter strategies were both shown to
signiﬁcantly reduce total cumulative doses of sedative
drugs without an increase in complications. More impor-
tantly, ventilator-free days, length of ICU stay, and
occurrence of posttraumatic stress syndrome were also
signiﬁcantly reduced [10–12]. Two meeting reports on
daily interruption in children presented a reduction of
midazolam dose in the intervention group; both studies
lacked power to show an effect on mechanical ventilation
or ICU stay [13, 14]. To our knowledge, there are no such
data on neonates or children on ECMO support.
The aim of our study is therefore to evaluate safety
and feasibility of initial interruption of analgesia and
sedatives in neonates following cannulation for ECMO.
Methods
Study design and setting
Prospective observational cohort study at a designated
ECMO center.
The institutional medical ethics review board
approved the study, and informed consent was obtained
from the parents or legal representatives.
Patients
All neonates \7 days old admitted for ECMO in 1 year
were eligible for enrolment.
Criteria for ECMO treatment were: gestational
age[34 weeks, birth weight[2.0 kg, mechanical ventilation
\7 days, alveolar arterial oxygen difference [600 mmHg,
and oxygenation index[25 for more than 6 h.
All received standardized anesthesia during cannula-
tion, consisting of fentanyl 5 mcg/kg bolus injection,
morphine 50 mcg/kg/u, and midazolam 200 mcg/kg/u
continuous infusion during cannulation. On ICU admis-
sion, severity of illness was assessed using the Score for
Neonatal Acute Physiology Version II (SNAP II) and the
Score for Neonatal Acute Physiology, Perinatal Exten-
sion, Version II (SNAPPE II).
Sedation and analgesia assessment
Pain and sedation were routinely assessed by the attend-
ing nurse using validated pain (visual analog scale, VAS)
and sedation (COMFORT-B) scores [15, 16]. Morphine
and midazolam infusions were discontinued 30–60 min
after cannulation and resumed on the guidance of regu-
larly determined CS and VAS scores.
When COMFORT-B score was 17 or higher, contin-
uous midazolam 100 mcg/kg/h was started after a loading
dose of 200 mcg/kg. Morphine 10 mcg/kg/u was started
after a loading dose of 100 mcg/kg when VAS score was
4 or higher, or when sedation was ineffective with
midazolam ([300 mcg/kg/u), or at the discretion of the
attending medical team. Fentanyl was used for procedural
analgesia or as rescue medication.
Outcome parameters
Primary: duration of sedation interruption
Secondary: need for rescue medication and number of
complications (extubations, decannulation,
impairment of ECMO ﬂow by 50%)
Statistical analysis
All values are presented as median (IQR) unless other-
wise indicated. Groups were compared using Mann–
Whitney test. For correlation analyses the Spearman
signed-rank test was used. A p value\0.05 was consid-
ered signiﬁcant. All statistical analyses were performed
using Graphpad Prism v4 (Graphpad Software Inc., La
Jolla CA, USA).
Results
Patient characteristics
Twenty-seven patients received ECMO support during the
study period. Twenty-one met the inclusion criterion, but
one of them died within 24 h after cannulation. So, the
analysisincluded20patients.Medianpostnatalage(range)
was 0.79 (0.17–5.8) days (Table 1). All patients received
midazolam median (IQR) 110 mcg/kg/u (100–200 mcg/
kg/u) and morphine 10.9 mcg/kg/u (10–20 mcg/kg/u)
1588before cannulation. Five received phenobarbital for sus-
pectedconvulsionspriortocannulationforECMO.Twelve
patients received vecuronium bromide prior to ECMO. All
patients received inotropic support and antibiotics.
Sedation interruption
Midazolam was discontinued in all 20 patients; morphine
in 18. Median interruption time for both drugs combined
was 10.3 h (IQR 5.0–24.1 h). Median interruption time
for midazolam was 16.5 h (IQR 6.6–29.6); median
interruption time for morphine was 11.2 h (IQR 6.7–
39.4 h) (Fig. 1). Interruption times were shorter for
patients with higher cumulative doses of midazolam or
morphine (r =- 0.54, p = 0.013 and r =- 0.58,
p = 0.008, respectively).
Interruptiontimesforpatientswithmeconiumaspiration
syndrome were shorter than for patients with other diag-
noses; the difference did not reach statistical signiﬁcance
[6.8 h (3.2–15.2 h) versus 16.0 h (8.7–35.1 h), p = 0.07].
Duration of interruption did not differ between
patients with and without concomitant phenobarbital use,
male and female patients, or survivors and nonsurvivors.
There was no signiﬁcant correlation between SNAP II or
SNAPPE II score and interruption time.
Safety
No accidental decannulations or extubations during
sedation interruption were observed, neither agitation
resulting in impairment of ECMO ﬂow nor accidental
bleeding.
Rescue medication
Three patients (15%) received fentanyl during the inter-
ruption period, one for perceived discomfort and two for
procedural analgesia.
Level of sedation
Both CS and VAS scores were low during sedation
interruption (Table 2). In seven patients (35%) midazo-
lam or morphine was restarted on the guidance of
Table 1 Clinical characteristics
Patients (n)2 0
Female/male (n) 10/10
Mortality (%) 25
CDH 7
MAS 10
Pneumonia 1
Sepsis 1
Pulmonary valve atresia 1
Median (IQR) (Range)
SNAP II 16 (16–23) (26–35)
SNAPPE II 33 (16–34) (16–54)
Oxygenation index prior to ECMO 38 (21–54)
AaDO2 prior to ECMO (mmHg) 599 (522–624)
Age (days) 0.79 (0.29–3.4) (0.17–6.8)
Length of ECMO (h) 123 (88–218) (53–462)
Gestational age (weeks) 40 1/7 (38 1/7–41 4/7) (35/5/7–42 3/7)
Birth weight (kg) 3.1 (2.8–3.6) (2.3–4.0)
Morphine dose pre-ECMO (mcg/kg/u) 10.9 (10–20) (8.8–33)
Midazolam dose pre-ECMO (mcg/kg/u) 110 (100–200) (50–220)
Data given are number of patients or median values (IQR) (range)
CDH congenital diaphragmatic hernia, MAS meconium aspiration syndrome, AaDO2 arterial alveolar oxygen difference
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Fig. 1 Individual interruption times of midazolam, morphine, and
of both sedatives. Each dot represents one patient
1589COMFORT-B score[17. In the other 13 patients either
no CS was recorded at the moment of restart of medica-
tion (n = 7) or midazolam or morphine was started
despite COMFORT-B or VAS score below the cutoff
point (n = 6). Reasons for start of medication were:
perceived discomfort manifesting as unexplained cardio-
vascular or respiratory instability, or suspected discomfort
in anticipation of a medical procedure.
Discussion
To our knowledge this is the ﬁrst study that shows that
prolonged interruption of sedatives and analgesics is
feasible in neonates on ECMO. Interruption of morphine
or midazolam did not cause any major complications. On
average, patients remained adequately sedated for 10 h
after cessation of medication. This is much longer than
reported in adult patients not on ECMO [8].
In the present study median COMFORT-B scores
during the study period were low overall: 8.5 (IQR8-9),
indicating oversedation [17]. In combination with pre-
dominantly low COMFORT-B and VAS scores at time of
restart of sedatives, this goes to show that, if anything,
sedation was reintroduced early rather than late. In line
with adult studies, interruption of medication seems more
effective in preventing oversedation than does protoco-
lized sedation alone.
Potentially altered disposition or effect of the drugs
given, due to age, pre-existing disease, cannulation or
ECMO treatment, could play a role in the longer inter-
ruption duration in our patients compared with adults. As
all were younger than 7 days, effect of age on interruption
duration could not be studied. We could not identify a
relation between critical illness scores and interruption
duration. Pharmacokinetic data of midazolam in these
patients show increased volume of distribution and
clearance on ECMO [18]. This suggests that the observed
interruption times are not related to increased plasma
levels on ECMO.
We did ﬁnd a shorter interruption duration in patients
with high cumulative doses of morphine and midazolam
prior to ECMO treatment, which could imply increased
tolerance to both drugs.
As a limitation of the study, there was a high per-
centage of protocol violation. In 60% of cases morphine
was started prior or simultaneously with midazolam; in
10% morphine was never discontinued. In all but one
patient VAS scores were below 4, indicating no pain at
time of morphine restart. Morphine was mostly used as a
sedative, either as ﬁrst choice or as an addition to
midazolam even when midazolam dose was below
300 mcg/kg/u. The attending physician was allowed to
deviate from protocol based on clinical assessment of the
patient. In many neonatal ICUs morphine is the sedative
of choice in ventilated (pre-)term infants, therefore
attending physicians may opt for morphine more easily
than for midazolam. Furthermore, procedures perceived
as painful may have elicited the choice for morphine as a
prophylactic analgesic. Due to these protocol violations it
is impossible to discriminate between the sedative effects
of midazolam and morphine in this study.
A second limitation lies in either missing or low
COMFORT-B scores at restart of medication. In two
patients medication was restarted prior to a procedure
without scores being performed. In nine patients nurses
indicated that the patient was uncomfortable or more
awake than deemed necessary, despite low COMFORT-B
scores. Ista et al. [17] showed that interpretation of CS
scores between 11 and 22 is difﬁcult in children on the
ICU and may necessitate an additional score.
Finally, doctors’ and nurses’ fear of accidental dec-
annulation or ECMO system failures may precipitate
earlier restart of sedatives. Our ﬁndings suggest that the
actual interruption duration could have been longer if
protocol compliance had been better.
Mulla et al. [19] reported 100% adequate sedation
with midazolam and morphine in a study cohort of 20
neonates on ECMO; unfortunately, dose adjustments were
not reported. Our ﬁndings are in line with previous studies
showing that, even if patients are oversedated and seda-
tion protocols dictate to lower doses of sedative drug,
these dose adjustments are not always made [20].
Conclusions
Interruptionof sedativesand analgesicsis feasible andsafe
in neonates on ECMO without increased risk of compli-
cations. Interruption times are 2–3 times longer than
reported in adult ICU patients. Future trials are needed to
substantiate these ﬁndings and evaluate outcome beneﬁts.
Table 2 Interruption duration, plasma levels, CS, and VAS at restart of medication
Median IQR Range
Interruption duration (h) 10:25 5:00–24:10 0:00–57:30
Median CS during cessation of medication 8.5 8–9 7–15
VAS 1 0–2 0–5
CS at restart of medication (n = 13) 17 11–18 10–21
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